Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 15:311:35-39.
doi: 10.1016/j.jneuroim.2017.07.014. Epub 2017 Jul 23.

Soluble membrane attack complex in the blood and cerebrospinal fluid of HIV-infected individuals, relationship to HIV RNA, and comparison with HIV negatives

Albert M Anderson  1 , Theresa N Schein  2 , Aley Kalapila  3 , Lillin Lai  3 , Drenna Waldrop-Valverde  4 , Raeanne C Moore  5 , Donald Franklin  5 , Scott L Letendre  6 , Scott R Barnum  2
Affiliations

Soluble membrane attack complex in the blood and cerebrospinal fluid of HIV-infected individuals, relationship to HIV RNA, and comparison with HIV negatives

Albert M Anderson et al. J Neuroimmunol. .

Abstract

The soluble membrane attack complex (sMAC) represents the terminal product of the complement cascade. We enrolled 47 HIV+ adults (12 of whom underwent a second visit at least 24weeks after starting therapy) as well as 11 HIV negative controls. At baseline, cerebrospinal fluid (CSF) sMAC was detectable in 27.7% of HIV+ individuals. CSF sMAC correlated with CSF HIV RNA levels and was more likely to be detectable in HIV+ individuals on cART compared to HIV negative controls. In HIV+ participants, there were negative association trends between sMAC and neurocognitive performance but these did not reach statistical significance.

Keywords: Acquired immunodeficiency syndrome; Complement; Human immunodeficiency virus; Membrane attack complex; Neurocognitive disorder.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest:

Theresa N. Schein, CEO / Co-Founder CNine Biosolutions, LLC.

Scott R. Barnum, CSO / Co-Founder CNine Biosolutions, LLC

Figures

Figure 1
Figure 1
Significant decrease in plasma sMAC concentration after 24 weeks of combination antiretroviral therapy (central line denotes mean)
Figure 2
Figure 2
CSF sMAC levels Visit 2= 24 weeks after cART initiation
Fig. 3
Fig. 3
See this image and copyright information in PMC

References

    1. Anderson AM, Munoz-Moreno JA, McClernon DR, Ellis RJ, Cookson D, Clifford DB, et al. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. The Journal of infectious diseases. 2017;215:105–13. - PMC - PubMed
    1. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–99. - PMC - PubMed
    1. Bejamini YH, Y Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B (Methodological) 1995;57:289–300.
    1. Blennow K, Fredman P, Wallin A, Gottfries CG, Karlsson I, Langstrom G, et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18–88 years of age. Eur Neurol. 1993;33:129–33. - PubMed
    1. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature medicine. 2006;12:1365–71. - PubMed

Publication types

MeSH terms